Investors & Media
With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to orphan pulmonary and fibrosis indications. Aileron intends to advance Lung’s pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01, for loculated pleural effusion (LPE).
Data Provided by Refinitiv. Minimum 15 minutes delayed.
October 31, 2023Aileron Therapeutics Announces Acquisition of Lung Therapeutics
February 21, 2023Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
November 30, 2022Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements